December 31, 2026
December 31, 2026
Pumili muna ng market
Pumili ng market sa listahan sa kaliwa para makita ang order book nito at mag-trade.
Pumili ng market sa kaliwa para makita ito.
Nangunguna ang December 31, 2026 sa 42% (53% isang linggo ang nakalipas). $5K na-trade sa kabuuan, $30 sa nakaraang 24 oras. Liquidity $160. Nakatakdang magsara sa 12/31/2026 (ET).
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Nangunguna ang December 31, 2026 sa 42% (53% isang linggo ang nakalipas). $5K na-trade sa kabuuan, $30 sa nakaraang 24 oras. Liquidity $160. Nakatakdang magsara sa 12/31/2026 (ET).
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.